GT201600250A - Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer - Google Patents
Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncerInfo
- Publication number
- GT201600250A GT201600250A GT201600250A GT201600250A GT201600250A GT 201600250 A GT201600250 A GT 201600250A GT 201600250 A GT201600250 A GT 201600250A GT 201600250 A GT201600250 A GT 201600250A GT 201600250 A GT201600250 A GT 201600250A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- salts
- tiadiazol
- gls1
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 102100025960 Glutaminase kidney isoform, mitochondrial Human genes 0.000 abstract 3
- 101000856990 Homo sapiens Glutaminase kidney isoform, mitochondrial Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 101710184006 Glutaminase 1 Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE EN FORMA GENERAL A COMPUESTOS SUSTITUIDOS DE 1,3,4,-TIADIAZOL Y A LAS SALES DE ELLOS ADECUADAS PARA USOS FARMACÉUTICOS. DICHOS COMPUESTOS ACTÚAN SOBRE LA ENZIMA GLUTAMINASA 1 ("GLS1"), Y LA PREVENCIÓN POR LO TANTO TAMBIÉN SE REFIERE AL USO DE DICHOS COMPUESTOS Y SALES PARA TRATAR O PREVENIR LAS ENFERMEDADES MEDIADAS POR GLS1, INCLUYENDO EL CÁNCER. LA PRESENTE INVENCIÓN SE REFIERE ASIMISMO A LAS FORMAS CRISTALINAS DE LOS COMPUESTOS SUSTITUIDOS DE 1,3,4-TIADIAZOL Y SALES ADECUADAS PARA USOS FARMACÉUTICOS; A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS Y SALES; A KITS QUE COMPRENDEN DICHOS COMPUESTOS Y SALES; A MÉTODOS DE PREPARACIÓN DE DICHOS COMPUESTOS Y SALES; Y A MÉTODOS PARA TRATAR ENFERMEDADES MEDIADAS POR LA QUINASA GLS1, INCLUIDO EL CÁNCER, UTILIZANDO DICHOS COMPUESTOS Y SALES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1409624.2A GB201409624D0 (en) | 2014-05-30 | 2014-05-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201600250A true GT201600250A (es) | 2019-06-10 |
Family
ID=51214473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201600250A GT201600250A (es) | 2014-05-30 | 2016-11-28 | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer |
Country Status (40)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) * | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| US9938265B2 (en) | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| TW201733587A (zh) * | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| TW201731511A (zh) * | 2015-11-30 | 2017-09-16 | 阿斯特捷利康公司 | １，３，４-噻二唑化合物及其在治療癌症中之用途 |
| ES2903182T3 (es) * | 2017-06-13 | 2022-03-31 | Medshine Discovery Inc | Compuesto como inhibidor GLS1 |
| JP2019064976A (ja) * | 2017-10-03 | 2019-04-25 | 国立大学法人 熊本大学 | 抗がん剤 |
| WO2020078350A1 (zh) * | 2018-10-16 | 2020-04-23 | 南京明德新药研发有限公司 | 噻二唑衍生物及其作为gls1抑制剂的应用 |
| SG11202109451TA (en) * | 2019-03-05 | 2021-09-29 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| WO2024233839A1 (en) * | 2023-05-10 | 2024-11-14 | Leal Therapeutics, Inc. | Small molecule inhibitors of glutaminase |
| CN116854582B (zh) * | 2023-07-10 | 2025-08-29 | 泰州葛林美克医药科技有限公司 | 一种对映纯α-甲氧基苯乙酸的制备方法 |
| CN117003745B (zh) * | 2023-07-20 | 2024-06-07 | 南京市第一医院 | Gls1/hdac双靶点抑制剂及其合成方法和应用 |
| WO2025196447A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
| WO2025196446A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ540161A (en) * | 2002-10-30 | 2008-03-28 | Vertex Pharma | Compositions useful as inhibitors of rock and other protein kinases |
| US20140186325A1 (en) | 2011-06-10 | 2014-07-03 | President And Fellows Of Harvard College | Methods of Cancer Treatment and Prevention Through the Modulation of SIRT4 Activity |
| ES2761866T3 (es) * | 2011-11-21 | 2020-05-21 | Calithera Biosciences Inc | Inhibidores heterocíclicos de glutaminasa |
| US9618514B2 (en) * | 2012-09-17 | 2017-04-11 | Agios Pharmaceuticals, Inc | Methods of evaluating patients using E-cadherin and vimentin |
| ES2899461T3 (es) | 2012-11-16 | 2022-03-11 | Calithera Biosciences Inc | Inhibidores heterocíclicos de glutaminasa |
| SG11201504022RA (en) | 2012-11-21 | 2015-06-29 | Agios Pharmaceuticals Inc | Glutamase inhibitors and method of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US9029531B2 (en) * | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| CN105283182A (zh) | 2012-12-03 | 2016-01-27 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶的杂环抑制剂治疗癌症 |
-
2014
- 2014-05-30 GB GBGB1409624.2A patent/GB201409624D0/en not_active Ceased
-
2015
- 2015-05-27 EA EA201692260A patent/EA030937B1/ru not_active IP Right Cessation
- 2015-05-27 AP AP2016009578A patent/AP2016009578A0/en unknown
- 2015-05-27 KR KR1020167036577A patent/KR20170005875A/ko not_active Abandoned
- 2015-05-27 SG SG11201609880QA patent/SG11201609880QA/en unknown
- 2015-05-27 PE PE2016002393A patent/PE20170148A1/es unknown
- 2015-05-27 HU HUE15726266A patent/HUE039879T2/hu unknown
- 2015-05-27 MY MYPI2016704405A patent/MY192861A/en unknown
- 2015-05-27 JP JP2017514983A patent/JP6538830B2/ja active Active
- 2015-05-27 RS RS20181101A patent/RS57876B1/sr unknown
- 2015-05-27 DK DK15726266.8T patent/DK3148994T3/en active
- 2015-05-27 TN TN2016000511A patent/TN2016000511A1/en unknown
- 2015-05-27 BR BR112016028002-4A patent/BR112016028002B1/pt active IP Right Grant
- 2015-05-27 WO PCT/GB2015/051537 patent/WO2015181539A1/en not_active Ceased
- 2015-05-27 CA CA2949598A patent/CA2949598C/en active Active
- 2015-05-27 LT LTEP15726266.8T patent/LT3148994T/lt unknown
- 2015-05-27 NZ NZ726790A patent/NZ726790A/en not_active IP Right Cessation
- 2015-05-27 EP EP15726266.8A patent/EP3148994B1/en active Active
- 2015-05-27 CN CN201580041233.9A patent/CN106795150B/zh active Active
- 2015-05-27 MX MX2016015738A patent/MX2016015738A/es unknown
- 2015-05-27 PT PT15726266T patent/PT3148994T/pt unknown
- 2015-05-27 SM SM20180516T patent/SMT201800516T1/it unknown
- 2015-05-27 SI SI201530403T patent/SI3148994T1/sl unknown
- 2015-05-27 US US15/314,562 patent/US10040788B2/en active Active
- 2015-05-27 ES ES15726266.8T patent/ES2688396T3/es active Active
- 2015-05-27 PL PL15726266T patent/PL3148994T3/pl unknown
- 2015-05-27 CR CR20160558A patent/CR20160558A/es unknown
- 2015-05-27 AU AU2015265703A patent/AU2015265703B2/en active Active
- 2015-05-27 HR HRP20181490TT patent/HRP20181490T1/hr unknown
- 2015-05-28 UY UY0001036145A patent/UY36145A/es not_active Application Discontinuation
- 2015-05-29 AR ARP150101720A patent/AR100694A1/es unknown
- 2015-05-29 TW TW104117531A patent/TWI693220B/zh not_active IP Right Cessation
-
2016
- 2016-11-17 IL IL249020A patent/IL249020B/en active IP Right Grant
- 2016-11-23 DO DO2016000308A patent/DOP2016000308A/es unknown
- 2016-11-28 GT GT201600250A patent/GT201600250A/es unknown
- 2016-11-29 CL CL2016003074A patent/CL2016003074A1/es unknown
- 2016-11-30 SV SV2016005330A patent/SV2016005330A/es unknown
- 2016-11-30 NI NI201600176A patent/NI201600176A/es unknown
- 2016-12-01 PH PH12016502394A patent/PH12016502394A1/en unknown
-
2018
- 2018-07-02 US US16/025,455 patent/US10294221B2/en active Active
- 2018-09-20 CY CY181100975T patent/CY1120836T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| NI201900062A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| ECSP19015192A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| NI201600115A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
| GT201600010A (es) | Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
| MX2013012053A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CO2018009563A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| MX389545B (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| CL2016002267A1 (es) | Ureas asimétricas p-sustituidas y usos médicos de las mismas | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2021000930A1 (es) | Piridazinas novedosas | |
| CL2018000391A1 (es) | Combinaciones farmacéuticas y su uso | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |